Modulation of γ-secretase by EVP-0015962 reduces amyloid deposition and behavioral deficits in Tg2576 mice.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101266600 Publication Model: Electronic Cited Medium: Internet ISSN: 1750-1326 (Electronic) Linking ISSN: 17501326 NLM ISO Abbreviation: Mol Neurodegener Subsets: MEDLINE
    • Publication Information:
      Original Publication: [London] : BioMed Central, 2006-
    • Subject Terms:
      Alzheimer Disease/*enzymology ; Amyloid Precursor Protein Secretases/*drug effects ; Amyloid beta-Peptides/*drug effects ; Behavior, Animal/*drug effects ; Biphenyl Compounds/*pharmacology ; Phenylpropionates/*pharmacology ; Propionates/*pharmacology; Amyloid Precursor Protein Secretases/metabolism ; Amyloid beta-Peptides/metabolism ; Animals ; Cell Line, Tumor ; Humans ; Mice ; Mice, Transgenic ; Transfection
    • Abstract:
      Background: A hallmark of Alzheimer's disease is the presence of senile plaques in human brain primarily containing the amyloid peptides Aβ42 and Aβ40. Many drug discovery efforts have focused on decreasing the production of Aβ42 through γ-secretase inhibition. However, identification of γ-secretase inhibitors has also uncovered mechanism-based side effects. One approach to circumvent these side effects has been modulation of γ-secretase to shift Aβ production to favor shorter, less amyloidogenic peptides than Aβ42, without affecting the overall cleavage efficiency of the enzyme. This approach, frequently called γ-secretase modulation, appears more promising and has lead to the development of new therapeutic candidates for disease modification in Alzheimer's disease.
      Results: Here we describe EVP-0015962, a novel small molecule γ-secretase modulator. EVP-0015962 decreased Aβ42 in H4 cells (IC50 = 67 nM) and increased the shorter Aβ38 by 1.7 fold at the IC50 for lowering of Aβ42. AβTotal, as well as other carboxyl-terminal fragments of amyloid precursor protein, were not changed. EVP-0015962 did not cause the accumulation of other γ-secretase substrates, such as the Notch and ephrin A4 receptors, whereas a γ-secretase inhibitor reduced processing of both. A single oral dose of EVP-0015962 (30 mg/kg) decreased Aβ42 and did not alter AβTotal peptide levels in a dose-dependent manner in Tg2576 mouse brain at an age when overt Aβ deposition was not present. In Tg2576 mice, chronic treatment with EVP-0015962 (20 or 60 mg/kg/day in a food formulation) reduced Aβ aggregates, amyloid plaques, inflammatory markers, and cognitive deficits.
      Conclusions: EVP-0015962 is orally bioavailable, detected in brain, and a potent, selective γ-secretase modulator in vitro and in vivo. Chronic treatment with EVP-0015962 was well tolerated in mice and lowered the production of Aβ42, attenuated memory deficits, and reduced Aβ plaque formation and inflammation in Tg2576 transgenic animals. In summary, these data suggest that γ-secretase modulation with EVP-0015962 represents a viable therapeutic alternative for disease modification in Alzheimer's disease.
    • References:
      Hippocampus. 2001;11(1):8-17. (PMID: 11261775)
      Neuron. 1998 Nov;21(5):1213-21. (PMID: 9856475)
      J Alzheimers Dis. 2010;19(1):311-23. (PMID: 20061647)
      J Alzheimers Dis. 2010;20(1):159-73. (PMID: 20164581)
      Physiol Rev. 2001 Apr;81(2):741-66. (PMID: 11274343)
      J Neurosci. 2000 Aug 1;20(15):5709-14. (PMID: 10908610)
      Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11049-53. (PMID: 10500121)
      J Neurosci. 2001 Jan 15;21(2):372-81. (PMID: 11160418)
      J Neurosci. 2002 Mar 1;22(5):1858-67. (PMID: 11880515)
      Alzheimers Res Ther. 2010 Dec 29;2(6):36. (PMID: 21190552)
      Cell. 2007 Oct 19;131(2):215-21. (PMID: 17956719)
      J Biol Chem. 2004 Mar 26;279(13):12876-82. (PMID: 14709552)
      Neuron. 2010 Sep 9;67(5):769-80. (PMID: 20826309)
      Nature. 2001 Nov 8;414(6860):212-6. (PMID: 11700559)
      J Neurochem. 2005 Oct;95(2):446-56. (PMID: 16086682)
      Nat Genet. 1994 Mar;6(3):251-5. (PMID: 8012386)
      Neurobiol Aging. 2000 May-Jun;21(3):383-421. (PMID: 10858586)
      J Neurosci. 2012 Feb 8;32(6):2037-50. (PMID: 22323718)
      JAMA. 2009 Dec 16;302(23):2557-64. (PMID: 20009055)
      Acta Neuropathol. 1991;82(4):239-59. (PMID: 1759558)
      Curr Alzheimer Res. 2011 Mar;8(2):164-74. (PMID: 21345170)
      J Clin Invest. 2003 Aug;112(3):440-9. (PMID: 12897211)
      J Neurochem. 2012 Jan;120 Suppl 1:109-124. (PMID: 22122663)
      J Biol Chem. 2001 Oct 26;276(43):40268-73. (PMID: 11518718)
      Neurosci Lett. 1996 Sep 13;215(3):173-6. (PMID: 8899741)
      Amyloid. 2007 Mar;14(1):39-50. (PMID: 17453624)
      J Cell Biol. 2009 May 4;185(3):551-64. (PMID: 19414612)
      Nature. 1999 Apr 8;398(6727):518-22. (PMID: 10206645)
      J Biol Chem. 2001 Apr 20;276(16):12991-8. (PMID: 11152675)
      J Biol Chem. 2012 Apr 6;287(15):11810-9. (PMID: 22334705)
      Arch Neurol. 2008 Aug;65(8):1031-8. (PMID: 18695053)
      J Biol Chem. 2003 Aug 22;278(34):31831-7. (PMID: 12805356)
      Nature. 1998 Jan 22;391(6665):387-90. (PMID: 9450754)
      Neurodegener Dis. 2011;8(6):455-64. (PMID: 21389687)
      Proc Natl Acad Sci U S A. 1985 Jun;82(12):4245-9. (PMID: 3159021)
      J Neurochem. 2002 Aug;82(3):563-75. (PMID: 12153480)
      Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1719-24. (PMID: 15665098)
      Expert Opin Investig Drugs. 2011 Mar;20(3):325-41. (PMID: 21222550)
      J Proteome Res. 2007 Nov;6(11):4433-9. (PMID: 17927230)
      J Med Chem. 2011 Feb 10;54(3):669-98. (PMID: 21141968)
      Neurobiol Dis. 2008 Jul;31(1):46-57. (PMID: 18504134)
      Curr Top Med Chem. 2011;11(12):1513-27. (PMID: 21510835)
      Int J Alzheimers Dis. 2010 Sep 02;2010:. (PMID: 20862386)
      Lancet Neurol. 2008 Jun;7(6):483-93. (PMID: 18450517)
      Science. 1996 Oct 4;274(5284):99-102. (PMID: 8810256)
      J Pharmacol Exp Ther. 2007 Dec;323(3):822-30. (PMID: 17895400)
      Exp Neurol. 2002 Feb;173(2):183-95. (PMID: 11822882)
      Neurobiol Aging. 2007 May;28(5):639-47. (PMID: 16697488)
      J Neurosci. 2005 Sep 28;25(39):8898-902. (PMID: 16192379)
      J Neurosci. 2003 Aug 20;23(20):7504-9. (PMID: 12930788)
      J Biol Chem. 2003 Aug 22;278(34):31825-30. (PMID: 12805355)
      Br J Pharmacol. 2011 May;163(2):375-89. (PMID: 21232036)
      Nat Rev Drug Discov. 2011 Aug 19;10(9):698-712. (PMID: 21852788)
      J Neurochem. 2006 Feb;96(3):732-42. (PMID: 16405513)
      Alzheimers Dement. 2011 May;7(3):263-9. (PMID: 21514250)
      J Neurosci Res. 1993 Aug 1;35(5):567-76. (PMID: 8377226)
      J Biol Chem. 2004 Oct 15;279(42):43419-26. (PMID: 15304503)
      Neuron. 1994 Jul;13(1):45-53. (PMID: 8043280)
      J Biol Chem. 2008 Oct 31;283(44):29615-9. (PMID: 18650430)
    • Accession Number:
      0 (2-(5-chloro-6-(2,2,2-trifluoroethoxy)-4'-(trifluoromethyl)biphenyl-3-yl)-3-cyclobutylpropanoic acid)
      0 (Amyloid beta-Peptides)
      0 (Biphenyl Compounds)
      0 (Phenylpropionates)
      0 (Propionates)
      EC 3.4.- (Amyloid Precursor Protein Secretases)
    • Publication Date:
      Date Created: 20121220 Date Completed: 20130730 Latest Revision: 20211021
    • Publication Date:
      20231215
    • Accession Number:
      PMC3573960
    • Accession Number:
      10.1186/1750-1326-7-61
    • Accession Number:
      23249765